menu
    • menu
    [{"orgOrder":0,"company":"RAND Corporation","sponsor":"National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Citalopram Hydrobromide","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"RAND Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RAND Corporation \/ National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham","highestDevelopmentStatusID":"11","companyTruncated":"RAND Corporation \/ National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham"}]

    Find Clinical Drug Pipeline Developments & Deals for CITALOPRAM, HYDROBROMIDE SALT

    Menu

    CITALOPRAM, HYDROBROMIDE SALT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            RAND Corporation

                            U.S.A arrow
                            FNCE
                            Not Confirmed

                            RAND Corporation

                            U.S.A arrow
                            FNCE
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Citalopram Hydrobromide

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase IV

                            Sponsor : National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Integrating a Stepped Care Model of Screening and Treatment for Depression Into Malawi's National HIV Care Del...

                            Details : Citalopram HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 02, 2021

                            Lead Product(s) : Citalopram Hydrobromide

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase IV

                            Sponsor : National Institute of Mental Health | Partners in Health | Brigham and Women's Hospital | Malawi Ministry of Health | Blantyre College of Medicine | University of Birmingham

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth